Developer docs
API playgroundTry for free, no card

Search company profiles

CoreMap

Full company profile

uuid0000drw

Namestring
CoreMap
Legal namestring
CoreMap Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

CoreMap is a private medical device company founded in 2016 by Dr. Peter Spector, a practicing clinical electrophysiologist, that develops ultra-high resolution electroanatomical mapping systems for the diagnosis and treatment of atrial fibrillation (AF). The company's system comprises the Invenio cardiac mapping catheter and the VidereX mapping workstation, designed to be used together during electrophysiology (EP) procedures in hospital catheterization labs. CoreMap's core technical differentiator is a tissue property mapping approach rather than conventional activation mapping, enabled by an orthogonal bipolar electrode configuration on the catheter that allows sequential data acquisition without the sample-density limitations of competing systems. The platform generates novel maps of atrial fibrillation using statistical analysis of data acquired from the ultra-high-resolution catheter.

CoreMap is pre-commercial and has not yet generated product revenue. The expected business model follows the standard EP lab device commercial pattern, with the Invenio catheter positioned as a single-use disposable and the VidereX workstation as installed capital equipment in EP labs at hospitals performing AF ablations; the target customer segment is practicing cardiac electrophysiologists and their EP lab teams. CoreMap holds ISO 13485 certification and received FDA Investigational Device Exemption (IDE) approval in May 2025 for the INvENI Map-Guided AF Ablation Study, positioning the company to begin U.S. clinical enrollment as a precursor to a future premarket approval (PMA) submission and commercial launch. CoreMap is headquartered in Burlington, Vermont, with an additional office in Burlington, Massachusetts, and operates with a headcount of 11–50 employees spanning engineering, data science, clinical, and regulatory functions.

Short descriptiontext

CoreMap is a private, pre-commercial medical device company developing ultra-high resolution electroanatomical mapping systems (Invenio catheter and VidereX workstation) for atrial fibrillation treatment, serving cardiac electrophysiologists in hospital EP labs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac electrophysiology mapping, atrial fibrillation ablation, electroanatomical mapping systems, high-resolution cardiac catheters, cardiac diagnostic devices
Industry1 code
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Other Measuring and Controlling Device Manufacturing334519
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Industrial Instruments For Measurement, Display, And Control3823
Product category
Cardiac Electrophysiology Mapping Systems
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

CoreMap is developing an electrophysiological mapping system (catheter and workstation) for atrial fibrillation treatment. The company is in pre-commercial stage with FDA IDE approval for clinical studies. Revenue will be generated through sale of the mapping system to hospitals and electrophysiology labs.

businesswire.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CoreMap is developing an advanced electrophysiological mapping system for atrial fibrillation treatment, consisting of the Invenio catheter (a high-resolution cardiac catheter with proprietary micro-electrodes) and the VidereX workstation (data processing and visualization platform). The system uses ultra-high resolution micro-electrode technology to map tissue properties rather than activation patterns, enabling electrophysiologists to identify AF drivers and deliver patient-specific ablation therapy. The device is currently investigational and not yet commercially available.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • CoreMap's ultra-high resolution electrodes reveal details of activation despite fibrillation complexity
Product overview1 text field

CoreMap offers a unified electroanatomical mapping platform for atrial fibrillation treatment. The system comprises two primary components: the Invenio catheter (an ultra-high resolution cardiac catheter with proprietary micro-electrode design for mapping tissue properties) and the VidereX workstation (for data processing and visualization). Together, these products enable identification of AF drivers and patient-specific treatment planning by generating high-resolution 3D electroanatomical maps during cardiac procedures. The company focuses on overcoming the limitations of traditional activation mapping through tissue property mapping that can be acquired sequentially, effectively eliminating sample density constraints.

Product and service3 records
1Invenio Catheter
CategoryCardiac mapping catheter
Description

A high-resolution cardiac catheter with proprietary ultra-high resolution micro-electrodes designed to capture detailed electrical properties of atrial tissue and identify atrial fibrillation drivers during cardiac ablation procedures. The catheter is intended for electrophysiologists performing AF ablation in hospital electrophysiology labs and is currently limited to investigational use.

2VidereX Workstation
CategoryElectroanatomical mapping workstation
Description

A workstation component of CoreMap's mapping system that processes and visualizes catheter data to enable electrophysiologists to identify AF drivers and support personalized, patient-specific treatment planning during cardiac ablation procedures. Currently limited to investigational use.

33D Electroanatomical Mapping System
CategoryCardiac electrophysiology mapping system
Description

A high-resolution, real-time 3D electroanatomical mapping system for use during cardiac procedures to guide ablation therapy. The system generates novel maps of atrial fibrillation using statistical analysis of data acquired from the Invenio ultra-high-resolution cardiac catheter, addressing the spatial resolution and sample density limitations of conventional mapping technologies. Currently investigational.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Biosense Webster (Johnson & Johnson)
TypeDirect peer
Description

Market-leading EP mapping and ablation franchise (CARTO 3 system) and CoreMap's primary direct competitor in cardiac electrophysiology mapping. Competes head-to-head for EP lab capital equipment and ablation catheter share.

TypeDirect peer
Description

Developer of the Rhythmia HDx mapping system and a broad ablation catheter portfolio. Directly competes with CoreMap in 3D electroanatomical mapping and AF ablation procedures.

3Abbott
TypeDirect peer
Description

Markets the EnSite X EP system and Advisor ablation catheters. One of the three dominant EP mapping competitors and a direct comparable to CoreMap's Invenio + VidereX platform.

4Acutus Medical
TypeEmerging player
Description

Pre-revenue/early-commercial competitor in high-resolution EP mapping with non-contact dipole charge-density mapping. Comparable as a smaller, technologically differentiated EP mapping peer targeting AF and complex arrhythmias.

TypeBroad incumbent
Description

Broad cardiac device incumbent with a cryoablation franchise and an evolving EP mapping presence. Provides strategic context as a potential acquirer or channel partner for CoreMap.

TypeEmerging player
Description

AI-based EP decision-support and mapping company focused on AF ablation. Comparable as a venture-stage peer leveraging data-driven approaches to improve AF procedural outcomes.

TypeEmerging player
Description

Developer of the Globe mapping and ablation system for AF. Direct emerging competitor pursuing a single-shot, all-in-one mapping and ablation workflow that overlaps with CoreMap's EP lab thesis.

8Adagio Medical
TypeEmerging player
Description

Developer of ultra-low-temperature cryoablation technology for AF and VT. Comparable as a venture-stage competitor focused on persistent AF, an indication CoreMap's tissue-property mapping also targets.

TypeEmerging player
Description

Non-invasive 3D cardiac arrhythmia mapping company. Comparable as a smaller peer pursuing advanced mapping methodologies to improve ablation targeting and procedural efficiency.

TypeEmerging player
Description

Developer of AI-enabled EP recording and signal-processing systems used during ablation procedures. Comparable as an emerging player whose signal-quality and analytics focus overlaps with CoreMap's mapping-workstation strategy.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CoreMap

Cardiac Electrophysiology Mapping Systemscoremapmedical.com

CoreMap is a private, pre-commercial medical device company developing ultra-high resolution electroanatomical mapping systems (Invenio catheter and VidereX workstation) for atrial fibrillation treatment, serving cardiac electrophysiologists in hospital EP labs.

What CoreMap does

CoreMap is a private medical device company founded in 2016 by Dr. Peter Spector, a practicing clinical electrophysiologist, that develops ultra-high resolution electroanatomical mapping systems for the diagnosis and treatment of atrial fibrillation (AF). The company's system comprises the Invenio cardiac mapping catheter and the VidereX mapping workstation, designed to be used together during electrophysiology (EP) procedures in hospital catheterization labs. CoreMap's core technical differentiator is a tissue property mapping approach rather than conventional activation mapping, enabled by an orthogonal bipolar electrode configuration on the catheter that allows sequential data acquisition without the sample-density limitations of competing systems. The platform generates novel maps of atrial fibrillation using statistical analysis of data acquired from the ultra-high-resolution catheter.

CoreMap is pre-commercial and has not yet generated product revenue. The expected business model follows the standard EP lab device commercial pattern, with the Invenio catheter positioned as a single-use disposable and the VidereX workstation as installed capital equipment in EP labs at hospitals performing AF ablations; the target customer segment is practicing cardiac electrophysiologists and their EP lab teams. CoreMap holds ISO 13485 certification and received FDA Investigational Device Exemption (IDE) approval in May 2025 for the INvENI Map-Guided AF Ablation Study, positioning the company to begin U.S. clinical enrollment as a precursor to a future premarket approval (PMA) submission and commercial launch. CoreMap is headquartered in Burlington, Vermont, with an additional office in Burlington, Massachusetts, and operates with a headcount of 11–50 employees spanning engineering, data science, clinical, and regulatory functions.

CoreMap firmographics

Firmographics
Name
CoreMap
Legal name
CoreMap Inc.
Website
https://coremapmedical.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
CoreMap is a private, pre-commercial medical device company developing ultra-high resolution electroanatomical mapping systems (Invenio catheter and VidereX workstation) for atrial fibrillation treatment, serving cardiac electrophysiologists in hospital EP labs.
Ownership category
akta.pro rank

CoreMap industry classification

Industry
Product category
Cardiac Electrophysiology Mapping Systems
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Other Measuring and Controlling Device Manufacturing (334519)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Industrial Instruments For Measurement, Display, And Control (3823)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • Cardiac electrophysiology mapping
  • Atrial fibrillation ablation
  • Electroanatomical mapping systems
  • High-resolution cardiac catheters
  • Cardiac diagnostic devices

Where CoreMap is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

CoreMap business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: CoreMap is developing an electrophysiological mapping system (catheter and workstation) for atrial fibrillation treatment. The company is in pre-commercial stage with FDA IDE approval for clinical studies. Revenue will be generated through sale of the mapping system to hospitals and electrophysiology labs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

CoreMap product offering

Product offering

Core offering

CoreMap is developing an advanced electrophysiological mapping system for atrial fibrillation treatment, consisting of the Invenio catheter (a high-resolution cardiac catheter with proprietary micro-electrodes) and the VidereX workstation (data processing and visualization platform). The system uses ultra-high resolution micro-electrode technology to map tissue properties rather than activation patterns, enabling electrophysiologists to identify AF drivers and deliver patient-specific ablation therapy. The device is currently investigational and not yet commercially available.

Product overview

CoreMap offers a unified electroanatomical mapping platform for atrial fibrillation treatment. The system comprises two primary components: the Invenio catheter (an ultra-high resolution cardiac catheter with proprietary micro-electrode design for mapping tissue properties) and the VidereX workstation (for data processing and visualization). Together, these products enable identification of AF drivers and patient-specific treatment planning by generating high-resolution 3D electroanatomical maps during cardiac procedures. The company focuses on overcoming the limitations of traditional activation mapping through tissue property mapping that can be acquired sequentially, effectively eliminating sample density constraints.

Differentiator

Problem solved

Functional benefit

Products and services

  • Invenio Catheter A high-resolution cardiac catheter with proprietary ultra-high resolution micro-electrodes designed to capture detailed electrical properties of atrial tissue and identify atrial fibrillation drivers during cardiac ablation procedures. The catheter is intended for electrophysiologists performing AF ablation in hospital electrophysiology labs and is currently limited to investigational use.
  • VidereX Workstation A workstation component of CoreMap's mapping system that processes and visualizes catheter data to enable electrophysiologists to identify AF drivers and support personalized, patient-specific treatment planning during cardiac ablation procedures. Currently limited to investigational use.
  • 3D Electroanatomical Mapping System A high-resolution, real-time 3D electroanatomical mapping system for use during cardiac procedures to guide ablation therapy. The system generates novel maps of atrial fibrillation using statistical analysis of data acquired from the Invenio ultra-high-resolution cardiac catheter, addressing the spatial resolution and sample density limitations of conventional mapping technologies. Currently investigational.

Quantifiable outcome

  • CoreMap's ultra-high resolution electrodes reveal details of activation despite fibrillation complexity

Companies that use CoreMap

Customer profile

Segments1 record

Ideal customer profiles1 record

CoreMap technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

CoreMap partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

CoreMap competitors and assessment

Company assessment

Direct peers

  • Biosense Webster (Johnson & Johnson): Market-leading EP mapping and ablation franchise (CARTO 3 system) and CoreMap's primary direct competitor in cardiac electrophysiology mapping. Competes head-to-head for EP lab capital equipment and ablation catheter share.
  • Boston Scientific: Developer of the Rhythmia HDx mapping system and a broad ablation catheter portfolio. Directly competes with CoreMap in 3D electroanatomical mapping and AF ablation procedures.
  • Abbott: Markets the EnSite X EP system and Advisor ablation catheters. One of the three dominant EP mapping competitors and a direct comparable to CoreMap's Invenio + VidereX platform.

Emerging players

  • Acutus Medical: Pre-revenue/early-commercial competitor in high-resolution EP mapping with non-contact dipole charge-density mapping. Comparable as a smaller, technologically differentiated EP mapping peer targeting AF and complex arrhythmias.
  • Volta Medical: AI-based EP decision-support and mapping company focused on AF ablation. Comparable as a venture-stage peer leveraging data-driven approaches to improve AF procedural outcomes.
  • Kardium: Developer of the Globe mapping and ablation system for AF. Direct emerging competitor pursuing a single-shot, all-in-one mapping and ablation workflow that overlaps with CoreMap's EP lab thesis.
  • Adagio Medical: Developer of ultra-low-temperature cryoablation technology for AF and VT. Comparable as a venture-stage competitor focused on persistent AF, an indication CoreMap's tissue-property mapping also targets.
  • APN Health: Non-invasive 3D cardiac arrhythmia mapping company. Comparable as a smaller peer pursuing advanced mapping methodologies to improve ablation targeting and procedural efficiency.
  • CathVision: Developer of AI-enabled EP recording and signal-processing systems used during ablation procedures. Comparable as an emerging player whose signal-quality and analytics focus overlaps with CoreMap's mapping-workstation strategy.

Broad incumbents

  • Medtronic: Broad cardiac device incumbent with a cryoablation franchise and an evolving EP mapping presence. Provides strategic context as a potential acquirer or channel partner for CoreMap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

CoreMap social profiles

Digital presence

CoreMap compliance and trust

Trust signal

Compliance1 record

CoreMap financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CoreMap leadership team

Management profile

Number of profiles

Profiles9 records

CoreMap funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CoreMap M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoreMap

What does CoreMap do?

CoreMap is developing an advanced electrophysiological mapping system for atrial fibrillation treatment, consisting of the Invenio catheter (a high-resolution cardiac catheter with proprietary micro-electrodes) and the VidereX workstation (data processing and visualization platform). The system uses ultra-high resolution micro-electrode technology to map tissue properties rather than activation patterns, enabling electrophysiologists to identify AF drivers and deliver patient-specific ablation therapy. The device is currently investigational and not yet commercially available.

Is CoreMap a public or private company?

CoreMap is a private company. It is classified as venture growth investor backed and is currently operating.

When was CoreMap founded?

CoreMap was founded in 2016. It employs 11 to 50 people.

Where is CoreMap based?

CoreMap is headquartered in Burlington, United States, in the North America region.

How does CoreMap make money?

One revenue line is on record: medical Device Sales.

Who are CoreMap's main competitors?

Direct peers on record are Biosense Webster (Johnson & Johnson), Boston Scientific and Abbott. Emerging players are Acutus Medical, Volta Medical, Kardium, Adagio Medical, APN Health and CathVision. Medtronic is listed as a broad incumbent.

Does CoreMap have an API?

No public API is recorded for CoreMap.

What industry is CoreMap in?

CoreMap's product category is Cardiac Electrophysiology Mapping Systems. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldCoremap raises $10.5M to advance AF mapping technologyAdvanced diagnostics startup Coremap Inc. secured $10.5 million in Series A financing led by Qure Ventures to advance its technology for identifying the drivers of atrial fibrillation. The funding will be utilized to accelerate product development and prepare for future regulatory submissions. This investment brings the Burlington, Vt.-based company's total capital raised to nearly $12 million since its founding in 2016.Current NewsCoreMap announces oversubscribed financing to advance next-gen A-fib mapping platformCoreMap, Inc., a medical technology company developing tools for atrial fibrillation treatment, announced the closing of a $37 million Series C financing round, led by Medtronic with participation from existing and new investors. The oversubscribed funding will accelerate the development of CoreMap's next-generation AF mapping platform designed to provide electrophysiologists with more precise data for guiding ablation treatments. The company, founded in 2016 and headquartered in Vermont and Massachusetts, cited strong investor confidence in its differentiated technology as the driver for this milestone.FinSMEsCoreMap Raises $37M in Series C FundingCoreMap, a Burlington, MA-based medical technology platform for atrial fibrillation mapping, raised $37M in Series C financing led by Medtronic. The company will use the funds to expand operations and development efforts. The platform provides electrophysiologists with tools for targeted AF treatments.Medical BuyerCoreMap raises USD 37M in Series C roundCoreMap, Inc. announced the closing of a $37 million oversubscribed Series C financing round led by Medtronic, with participation from existing and new investors. The funding will accelerate the development and market entry of CoreMap's next-generation atrial fibrillation mapping platform, reflecting investor confidence in the company's technology for improving AF treatment decisions and patient outcomes.Silicon RepublicMedtronic invests in CoreMap’s oversubscribed $37m Series C roundCoreMap, a US-based medtech company focused on atrial fibrillation diagnosis and treatment, has closed an oversubscribed $37 million Series C funding round led by Medtronic with participation from existing and new investors. The funds will support further development of CoreMap's electrophysiology mapping system designed to provide physicians with AF ablation guidance using large datasets of highly accurate electrical activation data. CoreMap's CEO Sarah Kalil called the financing a significant milestone that will accelerate the company's next-generation AF mapping platform's time to market.Simply Wall StMedtronic (MDT) Leads $37 Million CoreMap Funding Round To Back AF Mapping SystemMedtronic led a $37 million Series C funding round for CoreMap, a company developing an atrial fibrillation mapping and ablation system. The funding aims to support further development and commercialization of CoreMap's AF mapping technology, expanding Medtronic's involvement in cardiac arrhythmia treatment solutions.MedTech WorldCoreMap raises $37M in Medtronic-led funding round to advance atrial fibrillation mapping technologyCoreMap has raised $37 million in a Series C financing round led by Medtronic to enhance its electrophysiology mapping system for atrial fibrillation. This funding nearly doubles CoreMap’s total capital raised since its inception in 2016 and reflects a growing demand for precise technologies to improve patient outcomes during AF ablation procedures.YahooIs Medtronic’s Cannula Recall and CoreMap Investment Altering The Investment Case For Medtronic (MDT)?In late July 2026, Medtronic initiated a Class II recall of specific lots of its DLP One-Piece Pediatric Arterial Cannula, affecting worldwide distribution due to complaints of loose foreign material. Simultaneously, Medtronic led a $37 million Series C funding round for CoreMap to enhance electrophysiology mapping technology for atrial fibrillation. The developments highlight both quality-control issues and ongoing efforts to innovate in cardiac care.Cardiovascular BusinessMedtronic leads $37M investment in CoreMap’s AFib mapping techCoreMap has raised $37 million in Series C financing led by Medtronic, aimed at enhancing its AFib mapping technology. The funding will help CoreMap advance its platform to assist clinicians in treating atrial fibrillation more effectively. This investment is expected to expedite the technology's market entry, addressing a significant challenge in electrophysiology.YahooCoreMap raises $37m in Medtronic-led financing roundCoreMap, a Massachusetts-based medical device company, has raised $37 million in an oversubscribed Series C financing round led by Medtronic, with participation from new and existing investors. The funds will advance CoreMap's electrophysiology mapping system under development to support the treatment and diagnosis of atrial fibrillation, a heart condition that increases stroke risk fivefold according to the British Heart Foundation. CoreMap CEO Sarah Kalil stated the investment will accelerate the next-generation AF mapping platform's time to market to help electrophysiologists deliver more targeted, personalized treatment.